OCGN is at precarious levelOCGN fell out of its ascending Triangle formation and below the 21 EMA and even SARS indicator is saying sell. The only comforting news is that it is temporarily resting on and important support level.
OCGN trade ideas
Ocugen Inc.Explosive stock price soon
Buy signal triggered 💣 🚀
Target price - 9.85 $ - 12.00$ ----- it could reach 17.00 $
Ocugen Inc.This stock is currently accumulated in accumulation zone , and it could explosive very soon, Level 1.400 is very strong resistance level and if it breaks up , means a BUY signal triggered signal.
Buy signal triggered 💣💣💣💣💣🚀💯👌
OCGN 2W TF OCGN seems to have found support on the Arnaud Legoux Moving Average. The same area also has confluence with a 50% Fibonacci level. And also has confluence with a parallel structure.
There is hope.
Have a nice day
Unclear crossroads for OCGNOCGN daily timeframe.
OCGN appeared to just have completed a head and shoulders pattern and it is at a point where it may break the ascending triangle.
The SRSI is in the overbought region looking like it may signal a sell off, RSI numbers are low. The only favorable sign is that OCGN is still in the ascending triangle.
Have a great day
Bottoming at Higher LevelThe present range is valid since the end of March. Now we are at the bottom of the range and I expect it to go back to the to it's top, the more that the volatility is decreasing.
This range top has been the bottom from March to September 2022. Thus it might become a decisive resistance on a possible way up. But such a price above 2 would be a fine one.
Fork in the Road for OCGNThank you for your time.
Notice around the key level where OCGN is at now there were candlestick patterns with positive break outs.
It seems that OCGN is once again consolidating at a key level this time in an ascending triangle.
OCGN may break to the upside or break to the downside.
Have a great day
Ocugen Found BuyersOcugen found clear buying interest in a support area, where the price also closed an open gap.
As there are still net long positions at the highs of May 2024, we expect Ocugen's price to rise significantly in the near future.
ResistanceThis line seems to be important enough to initiate a regular correction. We may even chance to see a retracement of the rise since October.
Ocugen Is A BuyReasons why we are bullish on Ocugen:
Price found support in an order block; turning area confluent with the 50% retracement of the upward move between April 25, 2024 and May 16, 2024
Price was just able to overcome bearish order block to the upside
OCGN Ocugen Options Ahead of EarningsIf you haven`t bought OCGN when they released their Covid vaccine:
Then analyzing the options chain and the chart patterns of OCGN Ocugen prior to the earnings report this week,
I would consider purchasing the 1.50usd strike price Calls with
an expiration date of 2024-5-17,
for a premium of approximately $0.22.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Hidden ResistanceWe have retraced the decline since April 8th by over 50% and at the same time reached a hidden resistance which was the Summer low of 2022.
This allows the conclusion that the March-April double top may have formed the end of the attempt to turn around the downward trend existing since November 2021.
The present rise thus may be seen a an exhaustion already and the downward trend may be resumed.
Correction DueHaving Ocugen shorted has been one of my finest deals deals this year.
I was lucky enough to stay short until now.
But now I think that it's time for a correction. Not long ago there was a lot of buying phantasy among analysts and dealers. They have been disappointed.
What is the situation now? I think that the market is almost clean now. Disappointed traders have sold or were stopped out. Many of those who had bought after the gap on March 20th shall have sold as well as there hopes have not come true and may have vanished after a double top. To avoid loss even the latest may have sold today in fear that the March window might to be shut. Remain those who have bought in January and February. They have made good profit. But due to the heavy fluctuations in February and the double top this month many of them shall have taken profit over time not willing ti lose the good profit.
Due to the pressure this month the SEC has forbidden short selling of the stock, i.e. there shall not be many short position that may have to be covered.
That is why I think that the market is almost balanced now and open for fresh ideas.
SEC's ban of short selling is still valid and 1.28-1.35 is a resistance zone strong enough to halt the fall here having been the top on February 20th after the begin of the rise an then having been the bottom of the trading range before April 8th when markets became disappointed and fell.
If this zone will hold tomorrow we may see a new buying wave. Option traders may be willing to sell puts below the open window.
Bearish StartThe previous week could not reach the high of the week before. This was a hint that the bullish momentum is slowing down. The price reaction this week has confirmed this bias as the attempt to reached this high again has been sold immediately.
This high seems to become an important resistance zone as it was a support zone for half a year from March to September 2022 and even a several times tested support/resistance zone for 2 years from December 2020 until November 2022.
I see good chances therefor that this will defend its importance this time again.
OCGN pumps on dismissal of investor lawsuit LONGOCGN has been a great swing trade after buying bad news. The good news has replaced the
bad. Earnings are in three days. Price well below ATH. November earnings were a beat
meaning this risky Med Tech penny stock had a lower cash burn than projected. Now
legal costs will disappear. Going long with a decent position expecting a better earnings.
In law, the Latin phrase res ipsa loquitur is sometimes used. Here it aptly applies to
Ocugen.
Correction RetracedThe impressive correction 3 weeks ago of the little attempt to resume the long lasting decline since end 2020 is a signal that the market is still not convinced in a coming rebound of Ocugen.
We have just retraced the last branch of the downtrend which had lasted from July 2022 until the end of October 2023. Thus it may be a good time to find out the chances of another push. down.
Trading Idea - #OcugenMy trading idea for - #Ocugen - BUY
Entry: 0.95 USD
Target: 8.00 USD (+720% profit)
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Institutional Trading of Ocugen
A number of large investors have recently added their stakes in OCGN. JPMorgan Chase & Co. increased its holdings in Ocugen by 20.9% during the first quarter. JPMorgan Chase & Co. now owns 4,015,742 shares of the company's stock worth $13,251,000 after buying an additional 693,786 shares during the last quarter. Raymond James Financial Services Advisors Inc. purchased a new stake in Ocugen during the first quarter worth about $47,000. Cetera Investment Advisers purchased a new stake in Ocugen during the first quarter worth about $50,000. Vanguard Group Inc. increased its holdings in Ocugen by 2.8% during the first quarter. Vanguard Group Inc. now owns 10,906,557 shares of the company's stock worth $35,991,000 after buying an additional 301,063 shares during the last quarter. Finally, Mackenzie Financial Corp bought a new position in Ocugen during the first quarter worth about $34,000. Hedge funds and other institutional investors own 21.50% of the company's stock.
Ocugen Price Target Raised to $7.00/Share From $5.00 by HC Wainwright & Co.
OCGN - Currently FrolickingShe's currently dancing through monthly Supply Zone
- wait for the break out 5 Min, 15 Minute to be Safe
Looking for the orange squeezeer
OCGN Looking at this channel on ocgn. perhaps a break might occur.
Disclaimer- this is only for educational purposes, its neither a buy or sell recommendation. past results is not a guarantee for future returns.
$OCGN Ocugen Inc Long term PTs 16 - 21 - 180 and higherNASDAQ:OCGN Ocugen Inc
Long term PTs 16 - 21 - 180 and higher
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
